Abeona Therapeutics Inc. (ABEO) — Stock Score Summary

Abeona Therapeutics Inc. (ABEO) has a MoatMap StockRank of 69/100 based on Quality (52/100), Value (51/100), and Momentum (50/100) factor scores. The current signal is BUY. Abeona Therapeutics is a micro-cap gene therapy biotech. It lacks the high ROIC, established pricing power, and predictable cash flows required of a Terry Smith quality compounder, presenting binary clinical risk rather than asymmetric macro upside.

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for life-threatening rare genetic diseases. The company's competitive advantage is anchored by its proprietary retroviral vector platforms and state-of-the-art, in-house GMP manufacturing facility. Its lead clinical program targets recessive dystrophic epidermolysis bullosa (RDEB), positioning it as a specialized player in the high-value gene therapy sector.

Key Financial Metrics

Price$5.45
Market Cap$329M
P/E (TTM)5.74
P/E (Forward)19.03
Price/Book2.14
Return on Equity71.0%
Return on Invested Capital39.5%
Debt/Equity15.99
Gross Margin-123.8%
Operating Margin-264.1%
Free Cash Flow$-57M

Abeona Therapeutics Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Abeona Therapeutics Inc.’s (ABEO) StockRank?
MoatMap’s StockRank for Abeona Therapeutics Inc. (ABEO) is 69/100, with a Buy signal. It is a composite of Quality (52), Value (51), and Momentum (50) factor ranks across MoatMap’s 19,000+ stock universe.
Does Abeona Therapeutics Inc. have an economic moat?
Abeona Therapeutics Inc. (ABEO) has a Quality factor score of 52/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Abeona Therapeutics Inc. a buy, hold, or sell?
MoatMap’s current signal for Abeona Therapeutics Inc. (ABEO) is Buy, based on a StockRank of 69/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Abeona Therapeutics Inc. in?
Abeona Therapeutics Inc. (ABEO) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksABEO deep dive reportAI ChampionsHow we score stocksSense-check another stock